Meeting Coverage
ESMO Breast Cancer
European Society for Medical Oncology
No significant increased risk of recurrence or pregnancy complications
Latest ESMO Breast Cancer Meeting Coverage
No difference in survival versus chemotherapy alone in patients with PD-L1-positive disease
May 16, 2024
No PFS benefit with addition of ceralasertib to olaparib
May 5, 2022
High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial
May 4, 2022